利用转录因子驱动的ROS用于协同多模式肺癌治疗
Ye Zhou1, Simeng Wang1, Jiahua Guo1
1Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, PR China; Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, PR China.
这项研究引入了一种新的纳米平台,用于协同治疗肺癌,结合化疗,向治疗和放射治疗. 该平台使用多塞塔塞尔前药物和NRF2抑制剂来增强ROS生成和治疗疗效.
科学领域:
- 生物医学工程 生物医学工程
- 纳米医学是一种纳米医学.
- 在瘤学瘤学.
背景情况:
- 多模式癌症治疗提供了卓越的疗效,但在整合多种治疗方式方面面临着挑战.
- 设计能够管理不同药物的药理动力学特征的平台对于有效的癌症治疗至关重要.
研究的目的:
- 开发一种通用脂质纳米平台,用于肺癌中的协同化疗/向化疗/放射治疗.
- 设计一个系统,增强ROS生成,以获得持续的治疗效果.
主要方法:
- 一个脂质纳米平台的制造,封装了一个ROS可切割的多素前药物 (DTX-L-DTX) 和克洛贝塔索 (CP),一种NRF2抑制剂.
- 使用转录因子驱动的ROS自我可持续机制用于多模式癌症治疗.
- 整合化疗,向治疗和放射治疗,以获得协同效应.
主要成果:
- 该纳米药物证明了有效的分子向,化疗和放射治疗对肺癌的协同作用.
- ROS触发的多塞素释放启动了化疗,随后是CP介导的NRF2抑制,增强了向治疗和ROS生成.
- 放射治疗进一步放大了ROS,创造了一个积极的反循环,以提高治疗效率.
结论:
- 开发的纳米平台为多模式癌症治疗提供了一个简单而有效的策略.
- 这种方法解决了整合具有独特药理动力学特性的疗法所面临的挑战.
- 这项研究为临床癌症治疗及其他领域提供了有前途的解决方案.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
